Optimizing patient expectancy in the pharmacologic treatment of major depressive disorder

被引:0
|
作者
Zilcha-Mano, Sigal [1 ]
Brown, Patrick J. [2 ]
Roose, Steven P. [2 ]
Cappetta, Kiley [2 ]
Rutherford, Bret R. [2 ]
机构
[1] Univ Haifa, Dept Psychol, IL-31905 Haifa, Israel
[2] Columbia Univ Coll Phys & Surg, New York State Psychiat Inst, New York, NY 10032 USA
关键词
expectancy; major depressive disorder; placebo effects; PLACEBO-RESPONSE; BETWEEN-PERSON; WITHIN-PERSON; METAANALYSIS; DESIGN; ALLIANCE; QUESTION; MODELS;
D O I
10.1017/S0033291718003343
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background Patient expectancy is an important source of placebo effects in antidepressant clinical trials, but all prior studies measured expectancy prior to the initiation of medication treatment. Little is known about how expectancy changes during the course of treatment and how such changes influence clinical outcome. Consequently, we undertook the first analysis to date of in-treatment expectancy during antidepressant treatment to identify its clinical and demographic correlates, typical trajectories, and associations with treatment outcome. Methods Data were combined from two randomized controlled trials of antidepressant medication for major depressive disorder in which baseline and in-treatment expectancy assessments were available. Machine learning methods were used to identify pre-treatment clinical and demographic predictors of expectancy. Multilevel models were implemented to test the effects of expectancy on subsequent treatment outcome, disentangling within- and between-patient effects. Results Random forest analyses demonstrated that whereas more severe depressive symptoms predicted lower pre-treatment expectancy, in-treatment expectancy was unrelated to symptom severity. At each measurement point, increased in-treatment patient expectancy significantly predicted decreased depressive symptoms at the following measurement (B = -0.45, t = -3.04, p = 0.003). The greater the gap between expected treatment outcomes and actual depressive severity, the greater the subsequent symptom reductions were (B = 0.49, t = 2.33, p = 0.02). Conclusions Greater in-treatment patient expectancy is associated with greater subsequent depressive symptom reduction. These findings suggest that clinicians may benefit from monitoring and optimizing patient expectancy during antidepressant treatment. Expectancy may represent another treatment parameter, similar to medication compliance and side effects, to be regularly monitored during antidepressant clinical management.
引用
收藏
页码:2414 / 2420
页数:7
相关论文
共 50 条
  • [41] Escitalopram and citalopram in the treatment of major depressive disorder
    Andersen, HF
    Lam, RW
    NORDIC JOURNAL OF PSYCHIATRY, 2005, 59 (05) : 404 - 405
  • [42] The treatment of cognitive deficits in major depressive disorder
    Baldwin, David S.
    INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2013, 17 : 4 - 4
  • [43] Levomilnacipran for the treatment of major depressive disorder: a review
    Asnis, Gregory M.
    Henderson, Margaret A.
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2015, 11 : 125 - 135
  • [44] Duloxetine (Cymbalta) for treatment of major depressive disorder
    Cobb, C
    Crichlow, R
    AMERICAN FAMILY PHYSICIAN, 2005, 72 (06) : 1099 - 1101
  • [45] Exercise and pharmacotherapy in the treatment of major depressive disorder
    Blumenthal, James A.
    Babyak, Michael A.
    Doraiswamy, P. Murali
    Watkins, Lana
    Hoffman, Benson M.
    Barbour, Krista A.
    Herman, Steve
    Craighead, W. Edward
    Brosse, Alisha L.
    Waugh, Robert
    Hinderliter, Alan
    Sherwood, Andrew
    PSYCHOSOMATIC MEDICINE, 2007, 69 (07): : 587 - 596
  • [46] Advances in treatment for postpartum major depressive disorder
    Amodeo, Giovanni
    Laurenzi, Pier Francesco
    Santucci, Aurora
    Cuomo, Alessandro
    Bolognesi, Simone
    Goracci, Arianna
    Rossi, Rodolfo
    Beccarini Crescenzi, Bruno
    Neal, Stephen M.
    Fagiolini, Andrea
    EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (14) : 1685 - 1698
  • [47] Management of treatment resistance in major depressive disorder
    Suciu, B.
    Crisan, C.
    Miclutia, I.
    EUROPEAN PSYCHIATRY, 2018, 48 : S414 - S414
  • [48] Desvenlafaxine succinate for the treatment of major depressive disorder
    Lohoff, Falk W.
    Rickels, Karl
    EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (12) : 2129 - 2136
  • [49] Pharmacological treatment of major depressive disorder in adolescents
    Farley, Rachel L.
    THESCIENTIFICWORLDJOURNAL, 2005, 5 : 420 - 426
  • [50] Citalopram in the maintenance treatment of major depressive disorder
    Sonawalla, SB
    JOURNAL OF CLINICAL PSYCHIATRY, 2001, 62 (12) : 993 - 993